• Je něco špatně v tomto záznamu ?

Combined effect of lasioglossin LL-III derivative with azoles against Candida albicans virulence factors: biofilm formation, phospholipases, proteases and hemolytic activity

E. Vaňková, P. Kašparová, N. Dulíčková, V. Čeřovský

. 2020 ; 20 (3) : . [pub] 20200501

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21026713

Grantová podpora
NV16-27726A MZ0 CEP - Centrální evidence projektů

Candida albicans has several virulence factors at its disposal, including yeast-hyphal transition associated with biofilm formation, phospholipases, proteases and hemolytic activity, all of which contribute to its pathogenesis. We used synthetic derivative LL-III/43 of antimicrobial peptide lasioglossin LL-III to enhance effect of azoles on attenuation of C. albicans virulence factors. LL-III/43 was able to inhibit initial adhesion or biofilm formation of C. albicans strains at 50 µM. Azoles, however, were ineffective at this concentration. Using fluorescently labeled LL-III/43, we observed that peptide covered C. albicans cells, partially penetrated through their membranes and then accumulated inside cells. LL-III/43 (25 µM) in combination with clotrimazole prevented biofilm formation already at 3.1 µM clotrimazole. Neither LL-III/43 nor azoles were able to significantly inhibit phospholipases, proteases, or hemolytic activity of C. albicans. LL-III/43 (25 µM) and clotrimazole (50 µM) in combination decreased production of these virulence factors, and it completely attenuated its hemolytic activity. Scanning electron microscopy showed that LL-III/43 (50 µM) prevented C. albicans biofilm formation on Ti-6Al-4 V alloy used in orthopedic surgeries and combination of LL-III/43 (25 µM) with clotrimazole (3.1 µM) prevented biofilm formation on urinary catheters. Therefore, mixture of LL-III/43 and clotrimazole is suitable candidate for future pharmaceutical research.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026713
003      
CZ-PrNML
005      
20211026132700.0
007      
ta
008      
211013s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/femsyr/foaa020 $2 doi
035    __
$a (PubMed)32324227
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Vaňková, Eva $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo náměstí 542/2, 166 10, Prague, Czech Republic $u University of Chemistry and Technology Prague, Technická 5, 166 28, Prague, Czech Republic
245    10
$a Combined effect of lasioglossin LL-III derivative with azoles against Candida albicans virulence factors: biofilm formation, phospholipases, proteases and hemolytic activity / $c E. Vaňková, P. Kašparová, N. Dulíčková, V. Čeřovský
520    9_
$a Candida albicans has several virulence factors at its disposal, including yeast-hyphal transition associated with biofilm formation, phospholipases, proteases and hemolytic activity, all of which contribute to its pathogenesis. We used synthetic derivative LL-III/43 of antimicrobial peptide lasioglossin LL-III to enhance effect of azoles on attenuation of C. albicans virulence factors. LL-III/43 was able to inhibit initial adhesion or biofilm formation of C. albicans strains at 50 µM. Azoles, however, were ineffective at this concentration. Using fluorescently labeled LL-III/43, we observed that peptide covered C. albicans cells, partially penetrated through their membranes and then accumulated inside cells. LL-III/43 (25 µM) in combination with clotrimazole prevented biofilm formation already at 3.1 µM clotrimazole. Neither LL-III/43 nor azoles were able to significantly inhibit phospholipases, proteases, or hemolytic activity of C. albicans. LL-III/43 (25 µM) and clotrimazole (50 µM) in combination decreased production of these virulence factors, and it completely attenuated its hemolytic activity. Scanning electron microscopy showed that LL-III/43 (50 µM) prevented C. albicans biofilm formation on Ti-6Al-4 V alloy used in orthopedic surgeries and combination of LL-III/43 (25 µM) with clotrimazole (3.1 µM) prevented biofilm formation on urinary catheters. Therefore, mixture of LL-III/43 and clotrimazole is suitable candidate for future pharmaceutical research.
650    _2
$a antifungální látky $x farmakologie $7 D000935
650    _2
$a kationické antimikrobiální peptidy $x chemická syntéza $x farmakokinetika $7 D023181
650    _2
$a azoly $x farmakologie $7 D001393
650    _2
$a biofilmy $x účinky léků $x růst a vývoj $7 D018441
650    _2
$a Candida albicans $x účinky léků $7 D002176
650    _2
$a erytrocyty $x účinky léků $7 D004912
650    _2
$a hemolýza $x účinky léků $7 D006461
650    _2
$a lidé $7 D006801
650    _2
$a hydrofobní a hydrofilní interakce $x účinky léků $7 D057927
650    _2
$a proteasy $x metabolismus $7 D010447
650    _2
$a fosfolipasy $x antagonisté a inhibitory $7 D010740
650    _2
$a faktory virulence $7 D037521
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kašparová, Petra $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo náměstí 542/2, 166 10, Prague, Czech Republic $u University of Chemistry and Technology Prague, Technická 5, 166 28, Prague, Czech Republic
700    1_
$a Dulíčková, Nikola $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo náměstí 542/2, 166 10, Prague, Czech Republic $u University of Chemistry and Technology Prague, Technická 5, 166 28, Prague, Czech Republic
700    1_
$a Čeřovský, Václav $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo náměstí 542/2, 166 10, Prague, Czech Republic
773    0_
$w MED00006483 $t FEMS yeast research $x 1567-1364 $g Roč. 20, č. 3 (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32324227 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026132706 $b ABA008
999    __
$a ok $b bmc $g 1715450 $s 1147220
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 20 $c 3 $e 20200501 $i 1567-1364 $m FEMS yeast research $n FEMS Yeast Res $x MED00006483
GRA    __
$a NV16-27726A $p MZ0
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...